Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
M Bauer,1 J Bryce,2 P Hadji11University of Marburg, Marburg, Germany; 2National Cancer Institute, Naples, ItalyAbstract: Postmenopausal women have an increased risk of osteopenia and osteoporosis due to loss of the bone-protective effects of estrogen. Disease-related processes may also contribute to...
Saved in:
Main Authors: | Bauer M, Bryce J, Hadji P |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/5ee8db3a3ee946ffae223c84f4fcb28c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
by: Allan Lipton
Published: (2011) -
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
by: Schneider RE, et al.
Published: (2011) -
Decreased risk of breast cancer associated with oral bisphosphonate therapy
by: Mathew A, et al.
Published: (2012) -
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations
by: Neil M. Iyengar, et al.
Published: (2021) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
by: Mo QG, et al.
Published: (2016)